Stock Markets August 18, 2026 09:18 AM

Francisco Partners to Buy Weave Communications for $650 Million; Shares Jump in Premarket

Deal values Weave at $7.40 per share and would take the healthcare communications company private upon closing

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
WEAV

Weave Communications agreed to be acquired by private equity firm Francisco Partners for about $650 million, with Weave shareholders slated to receive $7.40 in cash per share. The announcement sent Weave stock sharply higher in premarket trading, and the company's board unanimously approved the transaction, which is expected to close in the fourth quarter of 2026 pending customary approvals.

Francisco Partners to Buy Weave Communications for $650 Million; Shares Jump in Premarket
WEAV
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Francisco Partners agreed to acquire Weave Communications for about $650 million, with stockholders to receive $7.40 per share in cash.
  • The $7.40 per-share offer represents about a 34% premium to Weave's closing price on August 17, 2026; Weave shares jumped 32.7% in Tuesday premarket trading following the announcement.
  • The Weave Board unanimously approved the transaction; closing is anticipated in the fourth quarter of 2026 pending stockholder approval and required regulatory clearances.

Weave Communications Inc will be acquired by Francisco Partners for approximately $650 million, the companies announced, a deal that pushed Weave shares up 32.7% in Tuesday premarket trading.

Under the terms agreed by the parties, each Weave stockholder will receive $7.40 in cash per share. That per-share consideration represents roughly a 34% premium to Weave's closing price on August 17, 2026, which the companies identified as the last full trading day prior to the announcement. Once the transaction is completed, Weave will stop trading on the NYSE and will transition to private ownership.

Weave describes itself as an AI-powered patient engagement and payments platform tailored to healthcare practices. Founded in 2008 and based in Lehi, Utah, the company says it serves more than 40,000 locations.

"Together with Francisco Partners, we will be able to enhance our ability to invest in our AI platform, deepen our payments and revenue cycle management capabilities, and further our vision of a better healthcare experience at every practice," said Brett White, Chief Executive Officer of Weave.

Stuart C. Harvey Jr., Chair of the Weave Board of Directors, said the Board conducted a thorough evaluation of strategic alternatives and spoke with a number of strategic and financial parties. The Board unanimously determined that this transaction represents the best path forward for Weave and recommends that stockholders vote in favor of the transaction.

The Weave Board of Directors gave unanimous approval to the deal. The parties expect the transaction to close in the fourth quarter of 2026, subject to customary closing conditions. Those conditions include approval by Weave stockholders and receipt of any required regulatory approvals.

Jefferies LLC is acting as exclusive financial advisor to Weave. Legal counsel to Weave is being provided by Orrick, Herrington & Sutcliffe LLP, while Kirkland & Ellis LLP is serving as legal counsel to Francisco Partners.


For investors and market participants tracking health-technology and payments platforms, the deal represents a definitive path for Weave to pursue further product investment and development under private ownership. The immediate market reaction was pronounced, with a premarket surge reflecting investor response to the cash consideration and premium on offer.

Key procedural milestones remain before closing, and the timetable and completion are contingent on the customary shareholder vote and regulatory clearances referenced by the companies. If completed as outlined, Weave will no longer trade publicly and will operate as a privately held business under Francisco Partners' ownership.

Risks

  • Completion of the acquisition is subject to customary closing conditions, including approval by Weave stockholders and receipt of required regulatory approvals, any of which could delay or prevent closing - impacts the healthcare technology and private equity sectors.
  • If the transaction does not close as expected, Weave will remain a public company and the current premium offered in the deal would no longer be guaranteed - affects shareholders and market pricing in healthcare software stocks.
  • Upon closing, Weave will cease trading on the NYSE and become privately held, which will reduce public market liquidity for the company's shares and change governance dynamics - relevant to investors and the health-tech market.

More from Stock Markets

Bloom Energy at a Crossroads: Momentum Meets Stretched Valuation Aug 18, 2026 ServiceNow Shares Rise After Dual Analyst Boosts Highlight AI and Security Growth Aug 18, 2026 Alibaba still trades beneath fair value as China-risk haircut endures Aug 18, 2026 The End of Cash Dominance: Where Institutional Investors Are Reallocating Aug 18, 2026 Cerebras Shares Retreat After Prior-Day Rally Ahead of SUPERNOVA Event Aug 18, 2026